Enhancing Source Credibility in Tobacco 
Regulatory Communications  
Center for Regulatory Research on Tobacco Communication, Project Credibility ( PI: Adam O. Goldstein)  
Version 6: Protocol for Publication 8/21/2020  
[STUDY_ID_REMOVED]  
  
2 
 Contents  
Administrative Information  ................................ ................................ ................................ ..........................  4 
Trial Registration  ................................ ................................ ................................ ................................ ................................ . 4 
Funding  ................................ ................................ ................................ ................................ ................................ ................  4 
Roles and Responsibilities  ................................ ................................ ................................ ................................ ...................  4 
Study Methods  ................................ ................................ ................................ ................................ ..............  5 
Population for this study  ................................ ................................ ................................ ................................ .....................  5 
Experime ntal Conditions  ................................ ................................ ................................ ................................ .....................  5 
Allocation and Blinding  ................................ ................................ ................................ ................................ .......................  5 
Messages  ................................ ................................ ................................ ................................ ................................ .............  6 
Study Flow  ................................ ................................ ................................ ................................ ................................ ...........  7 
Days 1 -15: Morning Surve ys ................................ ................................ ................................ ................................ ...............  8 
Message Order for Morning Surveys  ................................ ................................ ................................ ..............................  8 
Days 16 and 32: Post -test Surveys  ................................ ................................ ................................ ................................ ...... 9 
Compensation Plan  ................................ ................................ ................................ ................................ .............................  9 
Ethics and Trial Monitoring  ................................ ................................ ................................ .........................  10 
Data Safety  ................................ ................................ ................................ ................................ ................................ ........  10 
Monitoring  ................................ ................................ ................................ ................................ ................................ ........  10 
Declaration of Interests ................................ ................................ ................................ ................................ .....................  10 
Dissemination Plan  ................................ ................................ ................................ ................................ ............................  10 
Statistical Analysis Plan  ................................ ................................ ................................ ...............................  11 
Administration Information  ................................ ................................ ................................ ................................ ..............  11 
ClinicalTrials.gov ID  ................................ ................................ ................................ ................................ ...........................  11 
SAP Revision History  ................................ ................................ ................................ ................................ .........................  11 
Introduction  ................................ ................................ ................................ ................................ ................................ ...... 11 
Background and Rationale  ................................ ................................ ................................ ................................ ............  11 
Objectiv es ................................ ................................ ................................ ................................ ................................ ..... 11 
Study Methods  ................................ ................................ ................................ ................................ ................................ .. 11 
Trial Design ................................ ................................ ................................ ................................ ................................ .... 11 
Randomization  ................................ ................................ ................................ ................................ ..............................  12 
Sample Size  ................................ ................................ ................................ ................................ ................................ .......  12 
Sample Size Background : ................................ ................................ ................................ ................................ ..............  12 
Assumptions for the power calculation:  ................................ ................................ ................................ .......................  12 
Based on these assumptions:  ................................ ................................ ................................ ................................ .......  13 
How does this compare to KyungSu’s simulations?  ................................ ................................ ................................ ..... 13 
Recommendation:  ................................ ................................ ................................ ................................ ........................  13 
Framework  ................................ ................................ ................................ ................................ ................................ ........  14 
Statistical Interim Analyses and Stopping Guidance  ................................ ................................ ................................ .........  14 
Timing of Final Analysis  ................................ ................................ ................................ ................................ .....................  14 
Timing of Outcome Assessments  ................................ ................................ ................................ ................................ ...... 14 
Statistical Principles  ................................ ................................ ................................ ................................ ..........................  15 
Confidence Intervals and P Values  ................................ ................................ ................................ ................................  15 
Level of statistical significance  ................................ ................................ ................................ ................................ ...... 15 
Description and rationale for any adjustment for multiplicity and, if so detailing how the type 1 error is to be 
controlled  ................................ ................................ ................................ ................................ ................................ ...... 15 
Confid ence Intervals to be reported  ................................ ................................ ................................ .............................  15 
Adherence and Protocol Deviations  ................................ ................................ ................................ .............................  15 
Analysis Populations  ................................ ................................ ................................ ................................ .........................  15 
Definition of analysis populations  ................................ ................................ ................................ ................................  15 
Trial Population  ................................ ................................ ................................ ................................ ................................ . 16 
Screening Data  ................................ ................................ ................................ ................................ ..............................  16 
3 
 Eligibility  ................................ ................................ ................................ ................................ ................................ ........  16 
Recruitment  ................................ ................................ ................................ ................................ ................................ .. 17 
Withdrawal/follow -up ................................ ................................ ................................ ................................ ..................  18 
Baseline participant characteristics  ................................ ................................ ................................ ..............................  18 
Analysis ................................ ................................ ................................ ................................ ................................ ..............  19 
Outcome definitions  ................................ ................................ ................................ ................................ .....................  19 
Analysis Methods  ................................ ................................ ................................ ................................ ..............................  20 
Post test measures  ................................ ................................ ................................ ................................ ........................  20 
Daily Questionnaire Measures  ................................ ................................ ................................ ................................ ...... 21 
Harm s ................................ ................................ ................................ ................................ ................................ ................  21 
Statistical Software  ................................ ................................ ................................ ................................ ...........................  21 
References ................................ ................................ ................................ ................................ ................................ .........  21 
Appendix A: Study Measures  ................................ ................................ ................................ ......................  23 
Appendix B: Trial Consent Form  ................................ ................................ ................................ .................  51 
 
  
4 
 Administrative Information  
 
Trial Registration  
Enhancing Source Credibility in Tobacco Regulatory Communications, [STUDY_ID_REMOVED], 
https://clinicaltrials.gov/ct2/show/study/[STUDY_ID_REMOVED]  
Registration Date: November 13, 2017  
 
Funding  
Research reported in this publication was supported by grant number P50 CA180907 from the National Cancer Institute 
and the FDA Center for Tobacco Products (CTP). The content is solely the responsibility of the authors and does not 
necessarily represent the official views of the NIH or the Food and Drug Administration.  
 
Roles and Responsibilities  
Name  Role  Affiliation  
Adam O. Goldstein  Principal Investigator  Department of Family Medicine, University of North Carolina at 
Chapel Hill  
Lineberger Comprehensive Cancer Center, University of North 
Carolina at Chapel Hill  
Kristen L. Jarman  Project Manager  Lineberger Comprehensive Cancer Center, Universit y of North 
Carolina at Chapel Hill  
Sarah D. Kowitt  Doctoral Trainee  Department of Health Behavior , Gillings School of Global Public 
Health, University of North Carolina at Chapel Hill  
Bonnie E. Shook -Sa Doctoral Trainee  Department of Biostatistics, Gilli ngs School of Global Public 
Health, University of North Carolina at Chapel Hill  
Tara L. Queen  Statistician  Lineberger Comprehensive Cancer Center, University of North 
Carolina at Chapel Hill  
Kyung Su Kim  Statistician  Lineberger Comprehensive Cancer Center, University of North 
Carolina at Chapel Hill  
Leah M. Ranney  Co-Investigator  Department of Family Medicine, University of North Carolina at 
Chapel Hill  
Paschal Sheeran  Co-Investigator  Department of Psychology  and Neuroscience , University of 
North C arolina at Chapel Hill  
Seth M. Noar  Co-Investigator  Hussman School of Media and Journalism, University of North 
Carolina at Chapel Hill  
 
 
  
5 
 Study Methods  
Following a pilot to test intervention feasibility, conduct a randomized controlled trial (RCT) of 800 young adult and adult 
smokers to test the hypothesis that optimally framed (high source credibility) FDA cigarette constituent messages will 
increase int entions to quit more than sub -optimally framed (no source attached) cigarette constituent messages or 
control messages (littering). Messages will be presented in a web -enabled format, derived from cigarette constituent 
(hereafter referred to as constituent ) messages identified in Project 1 of our CRRTC, and framed based on the outcomes 
from Aim 2 of this project.  
Population for this study  
 
1. Age between 18 and 65  
2. Current Smoker  
3. Not currently enrolled in  a smoking cessation program  
4. Not currently using pharmaco therapy for smoking cessation  
5. Work or home access to the Internet  
6. Email account that they regularly use  
7. Have not participated in a smoking study, other than phone survey, in last 3 months  
8. Able to complete a survey on a computer  
9. Able to complete a survey in  English  
10. Able to complete surveys delivered via email  
11. Able to complete 3, 20 -minute, surveys  
12. Able to complete a 5 -min survey each morning for 15 days  
13. Lives in the US  
 
Experimental Conditions  
• Optimal Group: receive the risk and constituent messages with opt imized source depiction and engagement 
formats.  
• Suboptimal Group: receive the risk and constituent messages without source or engagement text.  
• Control Group:  receive littering messages  
 
Allocation and Blinding  
 
Participants will not be informed specifically about the possible interventions that they may be assigned to. Researchers 
will not be blinded to the condition that participants had been assigned to, however all outcome measures will be 
assessed via online survey.  
 
At the end of the baselin e survey, survey software will randomly assign participants to one of the three study arms. 
Participants will have an equal chance of being randomized to each study arm.  
 
  
6 
  
Messages  
Constituent Message  Words 
(Characters)  Littering Message  Words 
(Character s) 
 11 (76)  
 11 (74)  
 8 (59)  
 8 (55)  
 
8 (65)  
 8 (68)  

7 
  10 (70)  
 10 (74)  
 8 (65)  
 8 (61)  
 
Study Flow  
Pilot: Assess whether we can proceed and launch the full study when they have completed post -test 1, allow pilot 
participants to complete the full study  (through post -test 2 ). 
 
Full Study:  Baseline survey, then a survey every morning for 15 days assessing previous day behavior and delivering a 
message. Follow up with post surveys at day 1 6 and 3 2.  
 
Process:  
 
 
Day 0 -Pre-
TestDay 1
•Morning: 
View 
message and 
5 min survey
•Evening: 5 
min surveyDay 2 -5 
(Repeat Day 1 
with new 
messages)
•Morning: 
View 
message and 
5 min survey
•Evening: 5 
min surveyDay 6 -16 
(Repeat days 
1-5 2x)
•Morning: 
View 
message and 
5 min survey
•Evening: 5 
min surveyDay 16 -Post -
Test 1Day 32 -Post -
Test 2
8 
 Days 1 -15: Morning S urveys  
• There are 3 morning surveys, which align with each participant’s condition. Participants will stay in their 
condition throughout the study. Depending on the day, participants will see a different message.  
• The morning surveys will be sent out at 7am and will close at 10am. There will be a reminder email 
automatically sent at 8am if the participant has not yet completed the survey. The surveys will be sent according 
to each participant’s time zone.  
• At the end of the morning surveys, participants will s ee a message saying “You’ve completed [x] morning 
survey(s) so far. Keep up the good work!”  
• When each survey is emailed out, participants will receive a note that says “ If you have any problems, contact 
tobaccosurvey@unc.edu .” 
 
Message Order for Morning Su rveys  
• In week 1, participants see the following message order: 1 -2-5-3-4 (sequence 1)  
• In week 2, participants see the following message order: 2 -3-1-4-5 (sequence 2)  
• In week 3, participants see the following message order: 4 -3-5-2-1 (sequence 6)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conditions 1 and 2:  
• Message 1 = Ammonia  
• Message 2 = Arsenic  
• Message 3 = Formaldehyde  
• Message 4 = Lead  
• Message 5 = Uranium  
Condition 3:  
• Message 1 = Bearded man with red trash bin  
• Message 2 = Black man with yellow shirt  
• Message 3 = White man with blue shirt  
• Message 4 = Tan woman with orange hat and lots of cigarette butts in blue bin  
• Message 5 = Asian woman with cigarette butts in her hand  
 Day Message   Day Message  
Day 1  1  Day 1  1 
Day 8  1  Day 2  2 
Day 15  1  Day 3  5 
Day 2  2  Day 4  3 
Day 6  2  Day 5  4 
Day 14  2  Day 6  2 
Day 4  3  Day 7  3 
Day 7  3  Day 8  1 
Day 12  3  Day 9  4 
Day 5  4  Day 10  5 
Day 9  4  Day 11  4 
Day 11  4  Day 12  3 
Day 3  5  Day 13  5 
Day 10  5  Day 14  2 
Day 13  5  Day 15  1 
9 
 Days 16 and 32: Post -test Surveys  
• All participants wil l see the same post -test surveys.  
• The post -test surveys will be sent out at 7pm and will close 24 hours later. There will be a reminder email 
automatically sent at 8pm if the participant has not yet completed the survey. The surveys will be sent according 
to each participant’s time zone.  
 
Compensation Plan  
We will p ay participants $20 for the initial questionnaire an d post -test 1 and post -test 2. We will also p ay participants $4  
for each morning questionnaire.  
Bonus system for daily questionnaire completion:  
• Bronze: Total of $10 bonus for at least 9 morning surveys. 1 entry into a drawing for additional money.  
• Silver: Total of $20 bonus for at least 12 morning surveys. 2 entries into a drawing for additional money.  
• Gold: Total of $30 for completing all 15 morning surveys. 3 entries into a drawing for additional money.  
Participants may earn up to $150 for the f ull study, and will be paid via  check .  
 
Drawing for additional money : Three $200 checks will be administered  for Bronze, Gold or Silver participants are 
entered into based on how many daily questionnaires they complete.  
 
Participants  will receive  a message  at the end of each morning survey  regardi ng how many morning surveys they have 
completed . Participants will  be paid after the ir participation in the  study is completed.  
  
10 
 Ethics and Trial Monitoring  
 
This trial was approved by UNC’s IRB under IRB #17 -0610  
All protocol changes will be communicated to the study team, and any change in participant interaction will  be approved 
by UNC’s IRB.  
 
Data Safety  
This study proposes research that has been determined to include Security Level 2 data security requirements. I agree to 
accept responsibility for managing these risks appropriately in consultation with departmental and/or campus security 
personnel. The Data Security Requirements addendum can be reviewed here: 
https://guides.lib.unc.edu/datasecurity/irbis  
 
Monitoring  
This trial presents no more than minimal  risk to participants, so a data monitoring committee was not necessary. 
Similarly, the trial did not collect data on harms to participants, or assess interim data during the trial.  Similarly, there is 
no need for ancillary or post -trail care.  
 
Declaration  of Interests  
The study team declare that they have no competing interests.  
 
Dissemination Plan  
The study team plans to disseminate study findings via conference presentation and peer reviewed manuscripts in 
scientific journals. The study team will also share findings via ClinicalTrials.gov registration.  
 
We will follow authorship guidelines depending on the journal to which manuscripts are submitted.  
 
There are currently no plans to make a participant level dataset public.  
 
  
11 
 Statistical Analysis Plan  
 
Administration Information  
ClinicalTrials.gov ID  [STUDY_ID_REMOVED]  
SAP Revision History  
Version Number  Date  Summary of Changes  
1 July 24, 2018  SAP Created, agreed to by Adam O. Goldstein (Project PI), Tara L. Queen 
(Statistical Analyst), KyungSu Kim (Statistical Analyst), and Kristen L. Jarman 
(Study Coordinator, Document Originator)  
 
Introduction  
Background and Rationale  
The Family Smoking Prevention and Tobacco Control Act delegates the U.S. Food and Drug Administration (FDA) to 
communi cate the risks of smoking to the public, among other tobacco regulatory responsibilities. Little research  
exists about how FDA, as a regulatory agency, should develop and deliver these messages, and whether they should 
include their source information on t he ads. This study will assess the impact of cigarette constituent messages  
with and without FDA source and quit information in a randomized controlled trial. This study will assess the impact of 
cigarette constituent messages with and without FDA source a nd quit information in a randomized controlled trial.  
 
Objectives  
The investigators hypothesize that cigarette constituent messages will increase intention to quit compared to messages 
about littering cigarettes (the control). The investigators also hypot hesize that constituent messages that include FDA 
source and quit information will increase intention to quit compared to messages without that information.  
 
Study Methods  
Trial Design  
Three group parallel trial.  
 
The three conditions are:  
• Cigarette consti tuent message with FDA source and quit information : Messages about the chemical constituents 
of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, an 
image of a person related to the health effect. Thi s arm will also include an FDA logo, and information about the 
benefits of quitting smoking and the quitline. Each condition has 5 messages that will be repeated 3 times in a 
counterbalanced order. Study investigators used text developed by investigators a ssociated with our Center for 
Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.  
• Cigarette constituent message without FDA source or quit information : Messages about the chemical 
constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the 
chemicals, an image of a person related to the health effect. This arm is identical to the arm above, except that 
it does not include FDA source or quit informat ion. Each condition has 5 messages that will be repeated 3 times 
in a counterbalanced order. Study investigators used text developed by investigators associated with our Center 
for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.  
• Cigarette littering message (Control) : Messages about littering cigarettes will include text designed to discourage 
people from littering their cigarette butts, and an image related to the message. Each condition has 5 messages 
that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by 
12 
 investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these 
messages was developed by our team.  
 
Randomization  
At the end of the baseline survey, survey software will randomly assign participants to one of the three study arms. 
Participants will have an equal chance of being randomized to each study arm.  
 
Sample Size  
 
Sample Size Background:  
Our study is examining th e difference in quit intention for participants that receive 1) Optimal constituent messages 
with quitline information, and self -efficacy information, or 2) Sub -optimal constituent messages or 3) Messages about 
littering cigarette butts.  
 
No studies from t he literature that we could find examined difference in quit intention or quitting behaviors by optimal 
text vs. sub -optimal warning text vs. control in a warning or smoking communication context.  
 
In a meta -analysis by Noar et al. 2014 (Pictorial cigarett e pack warnings: a meta -analysis of experimental studies) the 
effect size between pictorial vs. text only warnings on intention to quit smoking was d=0.54. Other outcomes ranged 
between effect size d= -0.03 (recall of warning text), and d=1.82 (intention no t to start smoking).  
 
Assumptions for the power calculation:  
• The smallest effect size between our groups will be between the optimal and sub -optimal group. If we can see a 
difference between these groups, we will be able to see the larger effects that we expect between the other 
groups.  
• We will be using a continuous measure of quit intention (or treating quit intention as a continuous variable, and 
collecting it as a categorical response).  
• The effect size on quit intention is likely to be smaller for added  self efficacy and quit line text than for added 
pictorial images.  
• To be conservative, we will use a one time measure to calculate power, repeated measures would add power to 
this analysis (decrease necessary sample size).  
• We will use the d statistic to se e what group size would have to be enrolled, and compare two means (optimal 
and sub -optimal) with a t -test 
 
13 
 Based on these assumptions:  
 
 
The power calculation above is for a smaller effect size than the Noar 2016 paper, d=0.25. If we enroll 253 per group, we 
will have 80% power to detect a small difference between the optimal and sub -optimal group.  
 
For our purposes, that would mean enrolling a total of at least 759 people.  
 
How does this compare to KyungSu’s simulations?  
Based on Kyung Su’s simulati ons, if we use 3 time points, and enroll around 750 people, we should be able to see an 
effect size of 0.35. This simulation is also very dependent on the assumptions that we started with.  
 
Recommendation:  
To be even more conservative, I would like to enro ll at least 800 participants into our study to have enough power to see 
a d=0.25 difference between the optimal and sub -optimal groups.  

14 
  
Framework  
Superiority – standard hypothesis testing framework  
 
Statistical Interim Analyses and Stopping Guidance  
NA, t his study is no more than minimal risk to participants and does not pose a risk to their health, so we did not carry 
out any interim analyses or set guidelines for stopping the trial early.  
 
Timing of Final Analysis  
Final analysis will take place after all  data collection for the RCT is complete.  
 
Timing of Outcome Assessments  
Time  Pre-Test  Morning  Post -Test 1  Post -Test 2  
Constructs  • Sex, Sexuality  
• Hispanic Origin , 
Race  
• Address  
• Education  
• Age 
• Health  
• Household Size  
• Income (above or 
below FPL)  
• Trust in FDA and 
CDC 
• Nicotine 
Dependence 
(FTND)  
• Previous Quit 
Attempts  
• Smoking Status  
• Quit Intentions  
• Littering Intention  
• Self Efficacy  
• Response Efficacy  
• Positive and 
Negative Thoughts 
(Freq, Degree)  
• Current OTP Use  
• Knowledge of HE 
and Constituents  
• Tripartite Risk  
• Mental Health (K6)  
• Study Information  
• All Previous Day 
Behavior Qs  Previous day  behaviors:  
• Littering on the 
ground  
• Littering from Car  
• Forgoing  
• Butting out  
• Number of 
Cigarettes  
Cognitive Questions:  
• Thinking about 
chemicals  
• Thinking about risks  
• Thinking about 
littering  
• Thinking about 
quitting  
• Message  
• Negative Affect  
• Message Credibility  
• Perceived 
Effectiveness  • Nicotine 
Dependence 
(FTND)  
• Quit Attempts  
• Smoking Status  
• Quitline Awareness  
• Quitline Use  
• Quit Intentions  
• Quitline Intention  
• Littering Intention  
• Self Efficacy  
• Response Efficacy  
• Positive and 
Negative Thoughts 
(Freq, Degree)  
• Current OTP Use  
• Knowledge of HE 
and Constituents  
• Tripartite Risk  
• Credibility of FDA  
• Mental Health (K6)  
• Action 
Expectancies  
• Reactance  
• Talking about 
messages  
• All Previous Day 
Behavior Qs  
• Quality Assurance 
Questions  • Nicotine 
Dependence 
(FTND)  
• Quit Attempts  
• Smoking Status  
• Quitline Use  
• Quit Intentions  
• Quitline Intention  
• Littering Intention  
• Self Efficacy  
• Response Efficacy  
• Positive and 
Negative Thoughts 
(Freq, Degree)  
• Current OTP Use  
• Knowledge of HE 
and Constituents   
• Tripartite Risk  
• Mental Health (K6)  
• Action 
Expectancies  
• All Previous Day 
Behavior Qs  
15 
  
Statistical Principles  
Confidence Intervals and P Values  
Level of statistical significance  
α=0.05  
 
Description and rationale for any adjustment for multiplicity and, if so detailing how the type 1 error is to 
be controlled  
NA 
 
Confidence Intervals to be reported  
95% CI  
 
Adherence and Protocol Deviations  
Definition of adherence to the intervention and ho w this is assessed including extent of exposure  
Compliance with the protocol is assessed as follows:  
- Completion of daily surveys, during which participants view intervention stimuli. % Compliance = number of 
daily surveys completed / 15 (number of surveys supposed to be completed)*100%  
- Completion of post test surveys at post 1 and post 2  
 
Description of how adherence to the intervention will be presented  
- Adherence for the daily surveys will be presented with completion % as well as the mean number c omplete by 
treatment group  
- Completion of post test surveys will be presented by % completing each by treatment group  
 
Definition of protocol deviations for the trial  
- Minor protocol deviation: change in eligibility (ex: turning 66) between screening and bas eline  
- Minor protocol deviation: completing the wrong sequence of message days due to survey signal error  
- Major protocol deviation: No protocol deviations in this trial will impact the safety or physical or mental integrity 
of the participants in the trial.  A slightly older participant, or a participant that receives a slightly different 
number of messages will both be included as covariates during analysis, so they will not impact the scientific 
validity of the trial. Therefore, we do not classify any proto col deviations as ‘major’  
 
Description of which protocol deviations will be summarized  
- Protocol deviations will not be summarized overall, but data related to the deviations will be included in 
manuscripts. For example, we will not say X participants were older than 65, but will include mean age in a 
demographic table by treatment group. Similarly, we will not include how many people completed an extra ‘day’ 
of the protocol, but we will report the mean number of days participants completed  by treatment group.  
 
Analysis Populations  
Definition of analysis populations  
Outcomes assessed only at post test (including quit intentions) will be analyzed using multiple imputation such that 
everyone who was randomized will be included in the analysis,  and those with missing outcome data will have their 
outcomes imputed.  
 
16 
 For outcomes that were measured daily, all participants that completed at least one of the daily surveys will be included 
in the planned repeated measure models.  
 
Secondary outcomes ma y be analyzed using complete case analysis , without imputation.  
Trial Population  
Screening Data  
Screening data will be provided based on the CONSORT guidelines, and CONSORT flow chart will be included with 
publications.  
 
Eligibility  
Minimum Age: 18 Years  
Maximum Age: 65 Years  
Sex: All  
Gender Based: No  
Inclusion Criteria:  
• Have smoked at least 100 cigarettes in his or her lifetime  
• Currently smoke cigarettes every day or some days  
• Work or home access to the internet  
• Email account that is regularly used  
• Lives in the US  
• Comfortable taking a survey in English  
• Able to complete a survey on a computer  
• Able to complete surveys delivered via email  
• Able to complete 3, 20 minute surveys during the study  
• Able to complete surveys in the morning for 15 days  
Exclusion  Criteria:  
• Currently using pharmacotherapy, a quitline, or a quit smoking program or  support group for smoking cessation  
• Participated in a research study about smoking cigarettes or using other  tobacco products in the last 3 months  
  
17 
 Recruitment  
Recruitmen t data will be provided based on the CONSORT guidelines. The following CONSORT chart will be used as a 
template for reporting recruitment.  
 

18 
 Withdrawal/follow -up 
Level of withdrawal  
- Data collection and the intervention occur using the same surveys, when a participant withdraws from data 
collection, they are withdrawing from follow up and the intervention.  
 
Timing of withdrawal/lost to follow -up data  
- Timing of withdrawal will be presented by treatment group, and categorized into each of the following 
timepoints:  
o After baseline but before beginning intervention (before completing first daily survey)  
o During intervention (days 1 -15) 
o During post -test follow up period (days 16 -32) 
o After post -test follow up period (after day 32)  
 
Reasons and details of how w ithdrawal/lost to follow -up data will be presented  
- Numbers (with reasons) of loss to follow up and withdrawal over the course of the trial will be summarized by 
treatment group  
 
Baseline participant characteristics  
List of baseline characteristics to be su mmarized  
See Draft Table 1 below.  
Details of how baseline characteristics will be descriptively summarized  
Baseline characteristics will be descriptively summarized as show in Draft Table 1.S  
 
Draft Table 1. Baseline Sample Characteristics  
Sample Character istics  Condition 1 
(n=XXX)  Condition 2 
(n=XXX)  Condition 3 
(n=XXX)  Total Sample 
(n=XXX)  
  % or 
mean  95% 
CI % or 
mean  95% 
CI % or 
mean  95% 
CI % or 
mean  95% 
CI 
Gender          
 Male          
 Female          
Age, years          
Race          
 White          
 Black or African American          
 Other Race          
Ethnicity          
 Latino/Hispanic          
 Non -Latino/Hispanic          
Education          
 <High School (HS)          
 G12 or GED, HS Diploma          
 Some College          
19 
  Associate's degree          
 Bachelor's degree          
 Graduate or professional degree          
Poverty Status          
 Below Poverty Line          
 Above Poverty Line          
Sexual Orientation          
 Straight or heterosexual          
 Gay, lesbian, or bisexual          
Current Cigarette Smoking          
 Current smoker          
 Nonsmoker          
Fagerstrom Nicotine Dependence 
Score (FTND)          
Trust in FDA          
Number of Times Participants 
Viewed a Message During Follow Up          
To update Table 1 see ‘Table 1 V1.xlsx’ in Analysis Plan folder  
Analysis  
Outcome definitions  
• Quit intentions [ Time Frame: day 16 ] PRIMARY OUTCOME  
o 3 item measure with high reliability, average of the 3 items to create a score range 1 -4 (Brewer et al., 
2016, 2018; Klein, Zajac, & Monin, 2009)  
o We will compare the differences between pre and post  
• Number of cigarettes smoked each d ay [ Time Frame: Measured daily on days 1 -15] 
o Continuous, Modified from FTND (Heatherton, Kozlowski, Frecker, & Fagerström, 1991; Storr, 
Reboussin, & Anthony, 20 05) 
• Number of cigarettes forgone each day [ Time Frame: Measured daily on days 1 -15] 
o Continuous, adapted from Brewer 2016 (Brewer et al., 2016)  
o May be zero inflated, if yes, may choose to dichotomize to 0/1  
• Number of cigarettes butted out each day [ Time Frame: Measured daily on d ays 1 -15] 
o Continuous, adapted from Brewer 2016 (Brewer et al., 2016)  
o May be zero inflated, if yes, may choose to dichotomize to 0/1  
• Quit attempts during the study [ Time Frame: Measured on days 16 and 32 ]  
o Adaptation from Fagan (Fagan et al., 2007)  
o May be zero inflated, if yes, may choose to dichotomize to 0/1  
• Awareness of quitline [ Time Frame: Measured on day 16 ]  
• Recall of quitline phone number [ Time Frame: Measured on day 16 ]  
• Use of the quitline during the study [ Time Frame: Measured on days 16 and 32 ]  
• Intention to use the quitline [ Time Frame: Measured on days 16 and 32 ]  
• Quit intentions [Time Frame: Measured on day 32 ]  
o 3 item measure with high reliability, average of the 3 items to create a score range 1 -4 (Brewer et al., 
2016, 2018; Kle in et al., 2009)  
o We will compare the differences between pre and post  
• Self Efficacy [ Time Frame: Measured on days 16 and 32 ]  
20 
 o 1 item (“IARC HANDBOOKS OF CANCER PREVENTION,” n.d.; Thrasher, Swayampakala, Borland, et al., 
2016; Thrasher, Swayampakala, Cummings, et al., 2016)  
• Response Efficacy [ Time Frame: Measured on days 16 and 32 ]  
o 1 item (Thrasher, Swayampakala, Cummings, et al., 2016)  
 
Analysis Methods  
Analy sis methods will depend on the time point that the outcome was measured. Post test measures will be analyzed 
differently than measures from the daily surveys, as outlined below.  
Post test measures  
What analysis method will be used and how treatment effects  will be presented  
Linear regression for continuous outcomes, logistic for dichotomous.  
Any adjustment for covariates  
Covariates included for the imputation (in addition to treatment group):  
- Dose of ads (# of times participants viewed a message)  
- Gender (Ma le, Female, Other) (The GenIUSS Group, 2014)  
- Age (continuous)  
- Poverty Status (Above or Below Poverty Line) (Brewer et al., 2018; Department of Health and Human Services, 
2017)  
- Education (6 categori es, same as phone survey)  
- FTND Sum Using scoring from Heatherton et al. 1991 (Fagerstrom Test for Nicotine Dependence) (Fagerstrom, 
Heatherton, & Kozlowski, 1990; Heatherton et al., 1991)  
Covariates included in the analysis model (in additi on to treatment group):  
- Dose of ads (# of times participants viewed a message)  
Methods used for assumptions to be checked for statistical methods  
For continuous outcomes, we assume the distribution of dependent variable given a predictor variable (interven tion) is 
1) independent 2) normality 3) constant variance (homogeneity of variance). We can check normality with Q -Q plot of 
the residual or perform Wilk -Shapiro test  and use a scatter plot of residual on predictor variable (intervention) to check 
indepen dence and constant variance.  
Details of alternative methods to be used if distributional assumptions do not hold (eg normality, proportional 
hazards, etc)  
If we have a violation for normality assumption, we can have two options: 1) transform our data so th at the shape of our 
response variable become normally distributed or 2) choose the non -parametric method like Kruskal -Wallis which does 
not require the assumption of normality. The ANOVA can be considered a robust test against the normality assumption 
thou gh. If the assumption of homogeneity of variances has been violated, we can use Welch or Brown and Forsythe test. 
Even though we alternatively perform a Kruskal -Wallis test, in most cases, Welch test is best. We don’t expect to have 
dependency issues in ou r data.   
Any planned sensitivity analyses for each outcome where applicable  
Sensitivity analyses may be carried out using a ‘complete case analysis’ framework  
Any planned subgroup analyses for each outcome including how subgroups are defined  
None a priori  
Missing Data  
Multiple imputation will be used so that everyone who was randomized to an intervention will be included in the 
primary analysis  
Additional Analyses  
None a priori  
 
21 
 Daily Questionnaire Measures  
What analysis method will be used and how t reatment effects will be presented  
Mixed models to account for repeated measures of the same participant.  
Any adjustment for covariates  
Covariates included in the analysis model (in addition to treatment group):  
- Dose of ads (# of times participants viewed a message)  
Methods used for assumptions to be checked for statistical methods  
Linear mixed model is an extremely flexible for modeling continuous outcomes. It turns out that linear mixed models are 
robust to violations of some of their assumptions. The fol lowings are the assumptions for linear mixed model: 1) 
Independent (The outcomes of different people are assumed to be statistically independent of each other.) Note: the 
outcomes within a person are correlated. 2) Normality (random effects are assumed to be normally distributed with 
mean zero and the residuals are normally distributed.)  
Details of alternative methods to be used if distributional assumptions do not hold (eg normality, proportional 
hazards, etc)  
Because mixed models are robust to violations of some of their assumptions, we do not anticipate needing to use an 
alternative method.  
Any planned sensitivity analyses for each outcome where applicable  
None a priori  
Any planned subgroup analyses for each outcome including how subgroups are defined  
None a priori  
Missing Data  
Mixed models are appropriate to use and robust to missing data, so we will be able to include everyone who completed 
at least 1 daily questionnaire.  
Additional Analyses  
None a priori  
 
Harms  
Adverse events were not expected in this trial due to the minimal risks to participants, and no threat to participant 
health, so this section is not applicable.  
 
Statistical Software  
Statistical analyses will be conducted in SAS 9.4 (Cary, NC)  
 
References  
 
Final Dataset: rct_comb ined_07232018 [location removed]  
 
Data Cleaning Syntax: 01_Create_Analytic_Files.sas [location removed]  
 
Study Protocol: RCT_Protocol_V5 [location removed]  
 
Analysis plan compiled according to “Guidelines for the Content of Statistical Analysis Plans in Cl inical Trials” (Gamble et 
al., 2017)  
22 
  
Brewer, N. T., Hall, M. G., Noar, S. M., Parada, H., Stein -Seroussi, A., Bach, L. E., … Ribisl, K. M. (2016). Effect of Pictorial 
Cigarette Pack Warnings on Changes in Smoking Behavior: A  Randomized Clinical Trial. JAMA Internal Medicine , 
176(7), 905 –912. https://doi.org/10.1001/jamainternmed.2016.2621  
Brewer, N. T., Jeong, M., Mendel, J. R., Hall, M. G., Zhang, D., Parada, H., … Ribisl, K. M. (2018). Cigarette pack messages 
about toxic ch emicals: a randomised clinical trial. Tobacco Control , tobaccocontrol -2017 -054112. 
https://doi.org/10.1136/tobaccocontrol -2017 -054112  
Department of Health and Human Services. (2017). 2017 Annual Update of the HHS Poverty Guidelines . Federal Register  
(Vol. 82). Retrieved from https://www.gpo.gov/fdsys/pkg/FR -2017 -01-31/pdf/2017 -02076.pdf  
Fagan, P., Augustson, E., Backinger, C. L., O’Connell, M. E., Vollinger, R. E., Kaufman, A., … Gibson, J. T. (2007). Quit 
attempts and intention to quit cigarette smoking am ong young adults in the United States. American Journal of 
Public Health , 97(8), 1412 –1420. https://doi.org/10.2105/AJPH.2006.103697  
Fagerstrom, K. O., Heatherton, T. F., & Kozlowski, L. T. (1990). Nicotine addiction and its assessment. Ear, Nose, & Throat  
Journal , 69(11), 763 –765. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/2276350  
Gamble, C., Krishan, A., Stocken, D., Lewis, S., Juszczak, E., Doré, C., … Loder, E. (2017). Guidelines for the Content of 
Statistical Analysis Plans in Clinical Trials. JAMA , 318(23), 2337. https://doi.org/10.1001/jama.2017.18556  
Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., & Fagerström, K. O. (1991). The Fagerström Test for Nicotine 
Dependence: a revision of the Fagerström Tolerance Questionnaire. British Journal of Addiction , 86(9), 1119 –1127. 
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1932883  
IARC HANDBOOKS OF CANCER PREVENTION. (n.d.). International Agency for Research on Cancer World Health 
Organization , 12. Retrieved from http://www.iarc.fr/en/publicati ons/pdfs -
online/prev/handbook12/Tobacco_vol12_cover.pdf  
Klein, W. M. P., Zajac, L. E., & Monin, M. M. (2009). Worry as a Moderator of the Association Between Risk Perceptions 
and Quitting Intentions in Young Adult and Adult Smokers. Annals of Behavioral Me dicine , 38(3), 256 –261. 
https://doi.org/10.1007/s12160 -009-9143 -2 
Storr, C. L., Reboussin, B. A., & Anthony, J. C. (2005). The Fagerström test for nicotine dependence: A comparison of 
standard scoring and latent class analysis approaches. Drug and Alcohol Dependence , 80(2), 241 –250. 
https://doi.org/10.1016/j.drugalcdep.2004.04.021  
The GenIUSS Group. (2014). Best Practices for Asking Questions to Idenfity Transgender and Other Gender Minority 
Respondents on Population -Based Surveys . Retrieved from https://williamsinstitute.law.ucla.edu/wp -
content/uploads/geniuss -report -sep-2014.pdf  
Thrasher, J. F., Swayampakala, K., Borland, R., Nagelhout, G., Yong, H. -H., Hammond, D., … Hardin, J. (2016). Influences 
of Self -Efficacy, Response Efficacy, and Reactanc e on Responses to Cigarette Health Warnings: A Longitudinal Study 
of Adult Smokers in Australia and Canada. Health Communication , 31(12), 1517 –1526. 
https://doi.org/10.1080/10410236.2015.1089456  
Thrasher, J. F., Swayampakala, K., Cummings, K. M., Hammond, D., Anshari, D., Krugman, D. M., & Hardin, J. W. (2016). 
Cigarette package inserts can promote efficacy beliefs and sustained smoking cessation attempts: A longitudinal 
assessment of an innovative policy in Canada. Preventive Medicine , 88, 59–65. 
https://d oi.org/10.1016/j.ypmed.2016.03.006  
 
  
Appendix A: Study Measures  
 
Constructs by Timeframe  
Time  Pre-Test  Morning  Post -Test 1  Post -Test 2  
Constructs  • Sex, Sexuality  
• Hispanic Origin , Race  
• Address  
• Education  
• Age 
• Health  
• Household Size  
• Income (above or 
below FPL)  
• Trust in FDA and CDC  
• Nicotine Dependence 
(FTND)  
• Previous Quit 
Attempts  
• Smoking Status  
• Quit Intentions  
• Littering Intention  
• Self Efficacy  
• Response Efficacy  
• Positive and Negative 
Thoughts (Freq, 
Degree)  
• Current OTP Use  
• Knowledge of HE and 
Constituents  
• Tripartite RiskMental 
Health (K6)  
• Study Information  
• All Previous Day 
Behavior Qs  Previous day  behaviors:  
• Littering on the 
ground  
• Littering from Car  
• Forgoing  
• Butting out  
• Numb er of Cigarettes  
Cognitive Questions:  
• Thinking about 
chemicals  
• Thinking about risks  
• Thinking about 
littering  
• Thinking about 
quitting  
• Message  
• Negative Affect  
• Message Credibility  
• Perceived 
Effectiveness  • Nicotine Dependence 
(FTND)  
• Quit Attempts  
• Smoking Status  
• Quitline Awareness  
• Quitline Use  
• Quit Intentions  
• Quitline Intention  
• Littering Intention  
• Self Efficacy  
• Response Efficacy  
• Positive and Negative 
Thoughts (Freq, 
Degree)  
• Current OTP Use  
• Knowledge of HE and 
Constituents  
• Tripartite Risk  
• Credibility of FDA  
• Mental Health (K6)  
• Action Expectancies  
• Reactance  
• Talking about 
messages  
• All Previous Day 
Behavior Qs  
• Quality Assurance 
Questions  • Nicotine Dependence 
(FTND)  
• Quit Attempts  
• Smoking Status  
• Quitline Use  
• Quit Intentions  
• Quitline Intention  
• Littering Intention  
• Self Efficacy  
• Response Efficacy  
• Positive and Negative 
Thoughts (Freq, 
Degree)  
• Current OTP Use  
• Knowledge of HE and 
Constituents   
• Tripartite Risk  
• Mental Health (K6)  
• Action Expectancies  
• All Previous Day 
Behavior Qs  
 
24 
  
Pre, Post 1, Post 2  
 
Construct  
(Source)  Question Text  Response Option  Pretest Var Name  Post 1 Var Name  Post 2 Var Name  
Instruction  Please read the consent form on the next 
page to learn more about our research 
study and what we are asking participants 
to do.   Instruction    
Post 1 
Instruction  You have now finished the part of the study 
with daily surveys.  
 
This slightly longer survey should take you 
less than 20 minutes to complete. If you 
complete the survey, you will be paid an 
additional $20 in your incentive check.    Post1_Inst   
Post 2 
Instruction  This will be the last survey for this study. 
Thank you for your participation!  
 
This survey should take you less than 20 
minutes to complete. If you complete the 
survey, you will be paid an additional $20 in 
your incentive check.     Post2_Inst  
PAGE BREAK       Day 0 -Pre-TestDay 1
•Morning: View 
message and 5 
min survey
•Evening: 5 min 
surveyDay 2 -5 (Repeat 
Day 1 with new 
messages)
•Morning: View 
message and 5 
min survey
•Evening: 5 min 
surveyDay 6 -16 (Repeat 
days 1 -5 2x)
•Morning: View 
message and 5 
min survey
•Evening: 5 min 
surveyDay 16 -Post -Test 
1Day 32 -Post -Test 
2
25 
 Construct  
(Source)  Question Text  Response Option  Pretest Var Name  Post 1 Var Name  Post 2 Var Name  
Consent 
Form  [Include current consent form with 
agreement to participate]   ConsentForm1, 
ConsentForm_Gra
phic ConsentForm
2, ConsentForm3    
PAGE BREAK       
Sex11 What sex were you assigned at birth, on 
your o riginal birth certificate?  Was it…  1 = Male  
2 = Female  Sex1    
Sex21 Do you describe yourself as…  1= Male  
2= Female  
3= Transgender  
4= Other 
(specify______________)  Sex2 , Sex2_Text    
Sexua l 
Orientation2,3 Do you consider yourself to be…  1= Straight or heterosexual  
2= Gay or lesbian  
3= Bisexual  
4= OTHER 
(specify______________)  Sexuality , 
Sexuality_Text    
Page Break       
Hisp anic 
Origin3 Are you of Hispanic, Latino, or Spanish 
origin?  0= No  
1 = Yes  Hisp    
Race3 Which one of these groups would you say 
best represents your race?  1=White  
2=Black or African American  
3=American Indian or Ala ska 
Native  
4=Asian  
5=Pacific Islander  
6=Other  Race    
Page Break       
26 
 Construct  
(Source)  Question Text  Response Option  Pretest Var Name  Post 1 Var Name  Post 2 Var Name  
Instruction to 
provide 
name and 
address  Please provide your mailing address below. 
This is where we will send your incentive 
check at the end of the study.   Instr3    
First Name  First Name  Free Response  FirstName    
Last Name  Last Name  Free Response  LastName    
Address Line 
1 Street Number, Street Name  Free Response (Validity Check)  Addr1    
Address Line 
2 Apartment Number, Optional Address Line 
2 Free Response (Validity Check, 
Optional Response)  Addr2    
City City Free Response (Validity Check)  City   
Zip Zip Code  Free Response  Zip   
State  State  Dropdown list  
1= ALABAMA  
2= ALASKA  
3= ARIZONA  
4= ARKANSA S 
5= CALIFORNIA  
6= COLORADO  
7= CONNECTICUT  
8= DELAWARE  
9= DISTRICT OF COLUMBIA  
10= FLORIDA  
11= GEORGIA  
12= HAWAII  
13= IDAHO  
14= ILLINOIS  
15= INDIANA  
16= IOWA  
17= KANSAS  
18= KENTUCKY  
19= LOUISIANA  
20= MAINE  
21= MARYLAND  
22= MASSACHUSETTS  
23= MICHIGAN  
24= MINNESOTA  
25= MISSISSIPPI  State _0   
27 
 Construct  
(Source)  Question Text  Response Option  Pretest Var Name  Post 1 Var Name  Post 2 Var Name  
26= MISSOURI  
27= MONTANA  
28= NEBRASKA  
29= NEVADA  
30= NEW HAMPSHIRE  
31= NEW JERSEY  
32= NEW MEXICO  
33= NEW YORK  
34= NORTH CAROLINA  
35= NORTH DAKOTA  
36= OHIO  
37= OKLAHOMA  
38= OREGON  
39= PENNSYLVANIA  
(40=Puerto Rico* Option not displayed, 
included to align with screener for phone 
survey participants)  
41= RHODE ISLAND  
42= SOUTH CAROLINA  
43= SOUTH DAKOTA  
44= TENNESSEE  
45= TEXAS  
46= UTAH  
47= V ERMONT  
48= VIRGINIA  
49= WASHINGTON  
50= WEST VIRGINIA  
51= WISCONSIN  
52= WYOMING  
PAGE BREAK       
Time Zone  What time zone are you in?  -5=Eastern Standard Time (Ex: New York)  
-6=Central Standard Time (Ex: Chicago)  
-7=Mountain Standard Time (Ex: Salt Lake 
City)  
-8=Pacific Standard Time (Ex: Los Angeles)  
-9=Alaska Standard Time (Ex: Anchorage)  
-10=Hawaii -Aleutian Standard Time (Ex: 
Honolulu)  TimeZone    
PAGE BREAK       
Cell Phone 
Number  Do you have a cell phone?  1=Yes  
0=No  Cell_YN    
PAGE BREAK       
28 
 Construct  
(Source)  Question Text  Response Option  Pretest Var Name  Post 1 Var Name  Post 2 Var Name  
Cell Phone 
Number  Cell Phone Number  Free Response (Validity Check)  Phone_Number    
Page Break       
Education3 What is the highest degree or level of 
school you have completed?  [0= NO SCHOOLING COMPLETED  
1= NURSERY SCHOOL TO 4TH 
GRADE  
2= 5TH OR 6TH GRADE  
3= 7TH OR 8TH GRADE  
4= 9TH GRADE  
5= 10TH GRADE  
6= 11TH GRADE  
7= 12TH GRADE - NO DIPLOMA  
8= HIGH SCHOOL GRADUATE - 
high school diploma or the 
equivalent (for example: GED)  
9= SOME COLLEGE CREDIT, BUT 
LESS THAN 1 YEAR  
10= 1 OR MORE YEARS OF 
COLLEGE, NO DEGREE  
11= ASSOCIATE’S DEGREE (FOR 
EXAMPLE: AA, AS)  
12= BACHELOR’S DEGREE (FOR 
EXAMPLE: BA, AB, BS)  
13= MASTER’S DEGREE (FOR 
EXAMPLE: MA, MS, MEng, MEd, 
MSW, MBA)  
14= PROFESSIONAL DEGREE (FOR 
EXAMPLE: MD, DDS, DVM, LLB, 
JD) 
15= DOCTOR ATE DEGREE (FOR 
EXAMPLE: PhD, EdD)]  Edu   
29 
 Construct  
(Source)  Question Text  Response Option  Pretest Var Name  Post 1 Var Name  Post 2 Var Name  
Page Break       
Age How old are you?  Free response (Must be 3 or 
fewer numbers, between 18 -120)  Age   
General 
Health3 Would you say that in general your health 
is: 
 
 5= Excellent  
4= Very Good  
3= Good  
2= Fair  
1= Poor  Health    
Household4 How many people are in your household, 
including you?  # of people [restricted to 1 -10] Household    
Income4,5 [Ask only if Household  = 1, else skip to 
FTND 1 ] 
 
Which of the following cate gories best 
describes your total household income in 
the last 12 months?  1=Less than $12,060  
2=Between $12,060  and $18,089  
3=Between $18,090 and $24,119  
4=Between $24,120 and $30,149  
5=Between $30,150 and $36,179  
6=$36,180 or more  Income_1    
[Ask only if Household  = 2, else skip to 
FTND 1 ] 
 
Which of the following categories best 
describes your total household income in 
the last 12 months?  1=Less than  $16,240  
2=Between $16,240  and $24,359  
3=Between $24,360 and $32,479  
4=Between $32,480 and $40,599  
5=Between $40,600 and $48,719  
6=$48,720 or more  Income_2    
[Ask only if Household  = 3, else skip to 
FTND 1 ] 
 
Which of the following categories best 
describes your total household income in 
the last 12 months?  1=Less than  $20,420  
2=Between  $20,420  and $30,629  
3=Between $30,630 and $40,839  
4=Between $40,840 and $51,049  
5= Between $51,050 and $61,259  
6=$61,260 or more  Income_3    
[Ask only if Household  = 4, else skip to 
FTND 1 ] 
 1=Less than  $24,600  
2=Between  $24,600  and $36,899  
3=Between $36,900 and $49,199  Income_4    
30 
 Construct  
(Source)  Question Text  Response Option  Pretest Var Name  Post 1 Var Name  Post 2 Var Name  
Which of the following categories best 
describes your total household income in 
the last 12 months?  4=Between $49,200 and $61,499  
5=Between $61,500 and $73,799  
6=$73,800 or more  
[Ask only if Household  = 5, else skip to 
FTND 1 ] 
 
Which of the following categories best 
describes your total household income in 
the last 12 months?  1=Less than  $28,780  
2=Between  $28,780  and $43,169  
3=Between $43,170 and $57,559  
4=Between $57,560 and $71,949  
5=Between $71,950 and $86,339  
6=$86,430 or more  Income_5    
[Ask only if Household  = 6, else skip to 
FTND 1 ] 
 
Which of the following categories best 
describes your total household income in 
the last 12 months?  1=Less than  $32,960  
2=Between  $32,960  and $49,439  
3=Between $49,440 and $65,919  
4=Between $65,920 and $82,399  
5=Between $82,400 and $98,879  
6=$98,880 or more  Income_6    
[Ask only if Household  = 7, else skip to 
FTND 1 ] 
 
Which of the following categories best 
describes your total household income in 
the last 12 months?  1=Less than $37,140  
2=Betwee n $37,140  and $55,709  
3=Between $55,710 and $74,279  
4=Between $74,280 and $92,849  
5= Between $92,850 and 
$111,419  
6=$111,420 or more  Income_7    
[Ask only if Household  = 8, else skip to 
FTND 1 ] 
 
Which of the following categories best 
describes your total household income in 
the last 12 months?  1=Less tha n $41,320  
2=Betwee n $41,320  and $61,979  
3=Between $61,980 and $82,639  
4=Between $82,640 and 
$103,299  
5=Between $103,300 and 
$123,959  
6=$123,960 or more  Income_8    
[Ask only if Household  = 9, else skip to 
FTND 1 ] 
 1=Less than $45,500  
2=Between $45,500 and $68,249  
3=Between $68,250 and $90,999  Income_9    
31 
 Construct  
(Source)  Question Text  Response Option  Pretest Var Name  Post 1 Var Name  Post 2 Var Name  
Which of the following categories best 
describes your total household income in 
the last 12 months?  
 
 4=Between $91,000 and 
$113,749  
5=Between $113,750 and 
$136,549  
6=$136,500 or more  
[Ask only if Household  = 10, else skip to 
FTND 1 ] 
 
Which of the following categories best 
describes your total household income in 
the last 12 months?  1=Less than $49,680  
2=Between $49,680 and $74,519  
3=Between $74,520 and $99,359  
4=Between $99,360 and 
$124,199  
5=Between $124,200 and 
$149,039  
6=$149,040 or more  Income_10    
Page Break       
Trust in 
Gov3,6 How much trust do you have in the Federal 
government?  5= A great deal  
4= A fair amount  
2= Not very much  
1= None at all, or  
3= No opinion  TrustGov_Pre    
Trust in 
FDA3,6 In your opinion, does the  Food and Drug 
Administration , or FDA, give trustworthy 
information to the public?  5 = Definitely yes  
4 = Probably yes  
3 = Neither yes or no  
2 = Probably no  
1 = Definitely no  FDA_Pre    
Trust in 
CDC3,6 In your opinion, does the  Centers for 
Disease Control and Prevention, or  CDC, 
give trustworthy information to the public ? 5 = Definitely yes  
4 = Probably yes  
3 = Neither yes or no  
2 = Probably no  
1 = Definitely no  CDC_Pre    
Page Break       
Nicotine 
Dependence7 How soon after you wake up do you smoke 
your first cigarette?  3 = Within 5 minutes  
2 = 6 – 30 minutes  FTND1_Pre  FTND1_Post1  FTND1_Post2  
32 
 Construct  
(Source)  Question Text  Response Option  Pretest Var Name  Post 1 Var Name  Post 2 Var Name  
1 = 31 -60 minutes  
0 = After 60 minutes  
Do you find it difficult to refrain from 
smoking in places where it is forbidden e.g. 
in church, at the library, in cinema, etc.?  1 = Yes  
0 = No  FTND2_Pre  FTND2_Post1  FTND2_Post2  
Which cigarette would you hate most to 
give up?  1 = The first one in the morning  
0 = All others  FTND3_Pre  FTND3_Post1  FTND3_Post2  
Page Break       
Nicotine 
Dependence7 How many cigarettes per day do you 
smoke?  0 = 10 or less  
1 = 11 -20 
2 = 21 -30 
3 = 31 or more  FTND4_Pre  FTND4_Post1  FTND4_Post2  
Do you smoke more frequently during the 
first hours after waking than during the rest 
of the day?  1 = Yes  
0 = No  FTND5_Pre  FTND5_Post1  FTND5_Post2  
Do you smoke if you are so ill that you are 
in bed most of the day?  1 = Yes  
0 = No   FTND6_Pre  FTND6_Post1  FTND6_Post2  
Page Break       
Previous Quit 
Attempts8 How ma ny times during the past 12 months 
have you stopped smoking for 1 day or 
longer because y ou were trying to quit 
smoking?  Dropdown  (0-365)  PQA_Pre    
Quit 
Attempts8 Since you started this study, how many 
times have you stopped smoking for 1 day 
or longer because you were trying to quit 
smoking?    QuitAtt_Post1  
Dropdown 0 -16 QuitAtt_Post2  
Dropdown 0 -32 
Smoking 
Status9 Do you now smoke cigarettes every day, 
some days or not at all?  
 2=Every day  
1=Some days  
0=Not at all  Smoke_Stat_Pre  Smoke_stat_pos
t1 Smoke_Stat_post
2 
Page Break       
33 
 Construct  
(Source)  Question Text  Response Option  Pretest Var Name  Post 1 Var Name  Post 2 Var Name  
Quit Line 
Awareness  Do you know what national phone number 
you can call for help to quit smoking?  1 = Yes  
0 = No  
 (If no, skip the next question)   QLAware1   
Page Break       
Quit Line 
Awareness 
follow up  What is the national phone number?  Text Box   QLAware2   
Page Break       
Quitline Use  Since you started this study, have you  
called the Quitline (national phone number 
for help to quit smoking) ? 1 = Yes  
0 = No  
  QL_Use_Post1  QL_Use_Post2  
Page Break       
Quit 
Intention4,10 How interested are you in quitting smoking 
in the next month?  
 4=Very  interested  
3=Somewhat  interested  
2=A little  interested  
1=Not  at all interested  QI1_Pre  QI1_Post1  QI1_Post2  
How much do you plan to quit smoking in 
the next month?  
 4=Very much  
3=Somewhat  
2=A little  
1=Not at all  QI2_Pre  QI2_Post1  QI2_Post2  
How likely are you to quit smoking in the 
next month?  
 4=Very  likely  
3=Somewhat  likely  
2=A little  likely  
1=Not  at all likely  QI3_Pre  QI3_Post1  QI3_Post2  
PAGE BREAK      
Quitline 
Intention  If you were to quit smoking  in the next 
month , how likely are you to call the 
national quitline for help?  QLI_Pre  QLI_Post1  QLI_Post2  
Littering 
Intention4 How likely are you to dispose of your 
cigarette butts by dropping them on the 
ground in the ne xt month?  LI_Pre  LI_Post1  LI_Post2  
Page Break       
34 
 Construct  
(Source)  Question Text  Response Option  Pretest Var Name  Post 1 Var Name  Post 2 Var Name  
Self 
Efficacy11–13 If you decided to give up  smoking 
completely in the next month , how sure are 
you that you would succeed?  5=Extremely  
4=Very  much  
3=Moderately  
2=A little  
1=Not  at all SE_Pre  SE_Post1  SE_Post2  
Response 
Efficacy11 How much do you think you would benefit 
from health and other gains if you were to 
quit s moking per manently in the next 
month ? RE_Pre  RE_Post1  RE_Post2  
PAGE BREAK       
Positive 
Thoughts14,15 During the past 24 hours, how often did 
positive thoughts about smoking come to 
mind (thoughts that just popped into your 
head, or you caught yourself thinking)?  5=All  of the time  
4=Often  
3=Sometimes  
2=Rarely  
1=Never  Freq_Pos_Pre  Freq_Pos_Post1  Freq_Pos_Post2  
PAGE BREAK       
Positive 
Thoughts14,15 [displayed if freq_pos ne never]  
 
Considering only your positive thoughts 
about smoking during the past 24 hours, 
how positive were these thoughts?   1=Not at all Positive  
2=Slightly Positive  
3=Moderately Positive  
4=Very Positive  
5=Extremely Positive  Degree_Pos_Pre  Degree_Pos_Po
st1 Degree_ Pos_Post
2 
PAGE BREAK       
Negative 
Thoughts14,15 During the past 24 hours, how often did 
negative thoughts about smoking come to 
mind (thoughts that just popped into your 
head, or you caught yourself thinking)?  5=All  of the time  
4=Often  
3=Sometimes  
2=Rarely  
1=Never  Freq_Neg_Pre  Freq_Neg_Post1  Freq_Neg_Post2  
PAGE BREAK       
Negative 
Thoughts14,15 [displayed if freq_neg ne never]  
 
Considering only your negative thoughts 
about smoking during the past 24 hours, 
how negative were these thoughts?  1=Not at all Negative  
2=Slightly Negative  
3=Moderately Negative  
4=Very Negative  
5=Extremely Negative  Degree_Neg_Pre  Degree_Neg_Po
st1 Degree_Neg_Pos
t2 
Page Break       
35 
 Construct  
(Source)  Question Text  Response Option  Pretest Var Name  Post 1 Var Name  Post 2 Var Name  
Current OTP 
Use16 In the past 30 days, which of the following 
products have you used at least once? (Pick 
all that apply)  1. Cigars, cigarillos, or little 
cigars  
2. Smokeless tobacco, for 
example c hewing tobacco, 
snuff, dip , or snus  
 
3. Electronic cigarettes, e-
cigarettes , or other vaping 
devices  
4. Water pipes or Hookah  
5. Clove cigarettes  
6. Roll your own cigarettes  
7. None of the above [exclusive]  OTPUse_Pre 1, 
OTPUse_Pre2, 
OTPUse_Pre3, 
OTPUse_Pre4, 
OTPUse_Pre5,  
OTPUse_Pre6, 
OTPUse_Pre7    
OTP Use 216 Since you started this research study, which 
of the following products have you used at 
least once? (Pick all that apply)  1. Cigars, cigarillos, or little 
cigars  
2. Smokeless tobacco, f or 
example c hewing tobacco, 
snuff, dip , or snus  
3. Electronic cigarettes, e-
cigarettes , or other vaping 
devices  
4. Water pipes or Hookah  
5. Clove cigarettes  
6. Roll your own cigarettes  
7. None of the above [exclusive]   OTPUse_Post1_
1, 
OTPUse_Post1_
2, 
OTPUse_Post1_
3, 
OTPUse_Post1_
4, 
OTPUse_Post1_
5, 
OTPUse_Post1_
6, 
OTPUse_Post1_
7 OTPUse_Post2_1
, 
OTPUse_Post2_2
, 
OTPUse_Post2_3
, 
OTPUse_Post2_4
, 
OTPUse_Post2_5
, 
OTPUse_Post2_6
, 
OTPUse_Post2_7  
Page Break       
Knowledge17,
18 Does cigarette s moke contain…  
(Matrix Question)  1 = Yes  
0 = No  
2 = Don’t know  K_Inst1_Pre  K_Inst1_Post1  K_Inst1_Post2  
36 
 Construct  
(Source)  Question Text  Response Option  Pretest Var Name  Post 1 Var Name  Post 2 Var Name  
Arsenic   K_As_Pre  K_As_Post1  K_As_Post2  
Ammonia   K_Am_Pre  K_Am_Post1  K_Am_Post2  
Formaldehyde   K_Form_Pre  K_Form_Post1  K_Form_Post2  
Lead   K_Pb_Pre  K_Pb_Post1  K_Pb_Post2  
Uranium   K_U_Pre  K_U_Post1  K_U_Post2  
Page Break       
Knowledge17,
18 Does cigarette s moke  cause…  
(Matrix Question)  1 = Yes  
0 = No  
2 = Don’t know  K_Inst2_Pre  K_Inst2_Post1  K_Inst2_Post2  
Brain Disorders   K_BD_Pre  K_BD_Post1  K_BD_Post2  
Breathing Problems   K_BP_Pre  K_BP_Post1  K_BP_Post2  
Cancer   K_Cancer_Pre  K_Cancer_Post1  K_Cancer_Post2  
Heart Damage   K_HD_Pre  K_HD_Post1  K_HD_Post2  
Kidney Damage   K_KD_Pre  K_KD_Post1  K_KD_Post2  
Lung Tumors   K_LT_Pre  K_LT_Post1  K_LT_Post2  
Throat Cancer   K_TC_Pre  K_TC_Post1  K_TC_Post2  
Page Break       
Tripartite 
Risk19 If you continue smoking, how likely  is it 
that you…  (question in matrix format)  TR1 TR1 TR1 
will get heart damage at some point in the 
future?   
4=Very Likely  
3=Likely  
2=Unlikely  
1=Very Unlikely  
 TR1_a_Pre  TR1_a_Post1  TR1_a_Post2  
will get throat cancer at some point in the 
future?  TR1_b_Pre  TR1_b_Post1  TR1_b_Post2  
will get lung tumors at some point in the 
future?  TR1_c_Pre  TR1_c_Post1  TR1_c_Post2  
will get kidney damage at some point in the 
future?  TR1_d_Pre  TR1_d_Post1  TR1_d_Post2  
will get breathing problems at some point 
in the future?  TR1_e_Pre  TR1_e_Post1  TR1_e_Post2  
will get cancer at some point in the future?  TR1_f_Pre  TR1_f_Post1  TR1_f_Post2  
37 
 Construct  
(Source)  Question Text  Response Option  Pretest Var Name  Post 1 Var Name  Post 2 Var Name  
will get a brain disorder at some point in 
the future?  TR1_g_Pre  TR1_g_Post1  TR1_g_Post2  
Page Break       
Tripartite 
Risk19 If you continue smoking, how fearful  are 
you…  (question in matr ix format)  TR2 TR2 TR2 
of getting heart damage in the future?   
4=Very fearful  
3=Fearful  
2=A little fearful  
1=Not at all fearful  TR2_a_Pre  TR2_a_Post1  TR2_a_Post2  
of getting throat cancer in the future?  TR2_b_Pre  TR2_b_Post1  TR2_b_Post2  
of getting lung tumors in the future?  TR2_c_Pre  TR2_c_Post1  TR2_c_Post2  
of getting kidney damage in the future?  TR2_d_Pre  TR2_d_Post1  TR2_d_Post2  
of breathing problems damage in the 
future?  TR2_e_Pre  TR2_e_Post1  TR2_e_Post2  
of getting cancer in the future?  TR2_f_Pre  TR2_f_Post1  TR2_f_Post2  
of getting a brain disorder in the future?  TR2_g_Pre  TR2_g_Post1  TR2_g_Post2  
Page Break       
Tripartite 
Risk19 How much do you agree or disagree with 
the following statement: If I continu e to 
smoke, I feel very vulnerable to…  (question in matrix format)  TR3 TR3 TR3 
heart damage  4=Strongly Agree  
3=Agree  
2=Disagree  
1=Strongly Disagree  
 TR3_a_Pre  TR3_a_Post1  TR3_a_Post2  
throat cancer  TR3_b_Pre  TR3_b_Post1  TR3_b_Post2  
lung tumors  TR3_c_Pre  TR3_c_Post1  TR3_c_Post2  
kidney damage  TR3_d_Pre  TR3_d_Post1  TR3_d_Post2  
breathing problems  TR3_e_Pre  TR3_e_Post1  TR3_e_Post2  
cancer  TR3_f_Pre  TR3_f_Post1  TR3_f_Post2  
brain disorders  TR3_g_Pre  TR3_g_Post1  TR3_g_Post2  
Page Break       
FDA 
Information3,
6 The Food and Drug A dministration, or FDA, 
is the agency that ensures that food and 
drugs sold in this country are safe.  
   FDA_Info _Post1   
38 
 Construct  
(Source)  Question Text  Response Option  Pretest Var Name  Post 1 Var Name  Post 2 Var Name  
The FDA now regulates cigarettes and some 
other tobacco products.  The next series of 
questions is about your opinions toward 
FDA in this role.  
FDA 
Credibility3,6 Do you trust  the FDA to inform the public 
about the ri sks of tobacco products?  5 = Definitely yes  
4 = Probably yes  
3 = Neither yes or no  
2 = Probably no  
1 = Definitely no   Cred1 _Post1   
Is the FDA honest  about the risks of 
tobacco products?   Cred2 _Post1   
Do you believe  what the FDA says about 
the risks of tobacco products?   Cred3 _Post1   
Is the FDA an expert on regulating tobacco 
products?   Cred4 _Post1   
Is the FDA capable  of doing a good job 
regulating tobacco products?   Cred5 _Post1   
Can the FDA effectively  regulate tobacco 
products?   Cred6 _Post1   
Is the FDA committed  to protecting the 
public from possible risks of tobacco 
products?   Cred7 _Post1   
Do you believe that if the FDA knew that 
certain tobacco products are less harmful 
than thought, they would tell the public?   Cred8 _Post1   
Page Break       
Mental 
Health20 During the past 30 days, about how often 
did you feel…  (question in matrix format)  MH1  MH1  MH1  
nervous?  4=All of the time  
3=Most of the time  
2=Some of the time  
1=A little of the time  
0=None of the time  MH1 _a_Pre  MH1 _a_Post1  MH1 _a_Post2  
hopeless?  MH1 _b_Pre  MH1 _b_Post1  MH1 _b_Post2  
restless or fidgety?  MH1 _c_Pre  MH1 _c_Post1  MH1 _c_Post2  
so depressed that nothing could cheer you 
up? MH1 _d_Pre  MH1 _d_Post1  MH1 _d_Post2  
39 
 Construct  
(Source)  Question Text  Response Option  Pretest Var Name  Post 1 Var Name  Post 2 Var Name  
that everything was an effort?   
 MH1 _e_Pre  MH1 _e_Post1  MH1 _e_Post2  
worthless?  MH1 _f_Pre  MH1 _f_Post1  MH1 _f_Post2  
Page Break       
Instruction  Please select the bubble to answer the 
questions about the messages that you saw 
during the study :   AE_Inst_Post1  AE_Inst_Post2  
Action 
expectancies
21 After seeing the messages, how likely are 
you to seek information about chemicals in 
cigarettes?  4=Very Likely  
3=Likely  
2=Unlikely  
1=Very Unlikely   AE1_Post1  AE1_Post2  
After seeing the messages, how likely are 
you to seek help to quit smoking?  4=Very Likely  
3=Likely  
2=Unlikely  
1=Very Unlikely   AE2_Post1  AE2_Post2  
Page Break       
Instruction  Please select the bubble to show how much 
you agree or disagree with the statements 
below  about the messages that you saw 
during the study :   React   
Reactance22 The messages were trying to manipulate 
me 5=Strongly  agree  
4=Somewhat  agree  
3=Neither  agree  nor disagree  
2=Somewhat  disagree  
1=Strongly  disagree  
 
 
  React_1_Post1   
The message s made  me feel aggravated   React_2_Post1   
The health  effects on the  message s were  
overblown   React_3_Post1   
Page Break       
Conversation
s23,24 During the study, did you talk to others 
about the messages you received about 
cigarettes?  1=yes  
0=no   Convo1_Post1   
40 
 Construct  
(Source)  Question Text  Response Option  Pretest Var Name  Post 1 Var Name  Post 2 Var Name  
Page Break       
Conversation
s24 [only display if convo1_Post1 = 1]  
When you talked about the messages, 
would you say your conversations were 
mostly…  1=Negative about smoking 
cigarettes  
2=Neutral about smoking 
cigarettes  
3=Positive about smoking 
cigarettes   Convo2_Post1   
Page Break       
Behavior 
Instructions  Please think about yesterday   Behav_Inst  Behav_Inst  Behav_Inst  
 What time did you wake up yesterday?  Time  Time#1_Wake_Hour  
Time#1_Sleep_Hour  
Time#2_Wake_Min  
Time#2_Sleep_Min  
Time#3_Wake_AMPM  
Time#3_Sleep_AMPM   What time did you go to sleep last night?  Time  
Behavior4 How many times yesterday did you dispose 
of your cigarette butts by dropping them 
on the groun d? Dropdown list 0 -100, 
101=refused  Lit1 Lit1 Lit1 
How many times yesterday did you dispose 
of your cigarette butts by throwing them or 
dropping them out of the car window?  Lit2 Lit2 Lit2 
How many times yesterday did you stop 
yourself from having a cigarette because 
you wanted to smoke less?  Forgo  Forgo  Forgo  
How many times yesterday did you butt out 
a cigarette before you finished because you 
wanted to smoke less?  Butt  Butt  Butt  
PAGE BREAK       
Cigarettes 
Smoked7 Yesterday, from the time you woke up until 
noon, how many cigarettes did you smoke?  Dropdown list 0 -100, 
101=refused  Cigs_Morn  Cigs_Morn  Cigs_Morn  
41 
 Construct  
(Source)  Question Text  Response Option  Pretest Var Name  Post 1 Var Name  Post 2 Var Name  
Yesterday, from noon until you went to 
sleep, how many cigarettes did you smoke?  Cigs_Afternoon  Cigs_Afternoon  Cigs_Afternoon  
PAGE BREAK       
Thinking 
Instructions4 Overall yesterday, how much did you…   Think  Think  Think  
Thinking 
About 
Chemicals4 Think about the chemicals in the smoke 
from your cigarettes?  5=All  of the time  
4=Often  
3=Sometimes  
2=Rarely  
1=Never  Think_Chem  Think_Chem  Think_Chem  
Thinking 
About Risks  Think about the harm your smoking might 
be doing to you?  Think_Risk  Think_Risk  Think_Risk  
Thinking 
About 
Littering  Think about discarding cigarette butts 
properly?  Think_Lit  Think_Lit  Think_Lit  
Thinking 
about 
quitting  Think about quitting smoking?  Think_Quit  Think_Quit  Think_Quit  
PAGE BREAK       
StudyInfo1  The next few pages give you some more 
information for what to expect during the 
study.   StudyInfo1    
PAGE BREAK    PAGE BREAK    
StudyInfo2  Starting tomorrow, you will receive an 
email at 7am every morning for 15 days 
from ‘admin@SurveySignal.com’, with a 
link to a short survey. You have until 11am 
to open the link and answer the survey, or 
you will have to wait until the next one is 
sent.  
   StudyInfo2    
PAGE BREAK    PAGE BREAK    

42 
 Construct  
(Source)  Question Text  Response Option  Pretest Var Name  Post 1 Var Name  Post 2 Var Name  
StudyInfo4  After 15 days (16 days from now), you will 
receive another email at 7am with a link to 
a 20 -minute survey. You will have 24 hours 
to open the link and answer the survey.  
 
Finally, you will receive another email 32 
days from now with a link to a 20 -minute 
survey. You will have 24 hours to open the 
link and answer the survey.   StudyInfo4    
PAGE BREAK    PAGE BREAK    
StudyInfo5  You will be paid for the study based on how 
many surveys you complete with a check 
that will arrive in the mail after you 
complete the study.  
 
You will receive $20 for completing this 
survey.  
 
For the daily morning surveys, you will be 
paid $4 for each survey that you complete.  
 
For the 20 -minute surveys at the end of the 
study, you will receive $20 each if you 
complete them.  
 
When data collection for the full study is 
complete, we will have a drawing for three 
Amazon gift cards, with a $200 value. 
Entri es into the drawing will be based on 
completion of the morning surveys.  
Bonus system for Morning Survey 
Completion:  
• Bronze: Total of $10 bonus for at least 9 
morning surveys. 1 entry into Amazon 
gift card drawing.   StudyInfo5    
43 
 Construct  
(Source)  Question Text  Response Option  Pretest Var Name  Post 1 Var Name  Post 2 Var Name  
• Silver: Total of $20 bonus for at least fo r 
at least 12 morning surveys. 2 entries 
into Amazon gift card drawing.  
• Gold: Total of $30  bonus  for completing 
all 15 morning surveys. 3 entries into 
Amazon gift card drawing.  
If you complete all the surveys for this 
study, your check amount will be $150.  
PAGE BREAK       
Quality 
Assurance  When you took the surveys, ere you able to 
see each message?  0=No  
1=Yes   QA1   
PAGE BREAK       
Quality 
Assurance  [IF QA1 = No] Why weren’t you able to see 
each message , when you took the surveys ? [text box]   QA1 _comment   
PAGE BREAK       
Quality 
Assurance  Were you able to read the text on each of 
the messages?  0=No  
1=Yes   QA2   
PAGE BREAK       
Quality 
Assurance  [IF QA2 = No] Why weren’t you able to read 
the text on each of the messages?  [text box]   QA2_comment   
PAGE BREAK       
Quality 
Assurance  Did you understand all of the questions?  0=No  
1=Yes   QA3   
PAGE BREAK       
Quality 
Assurance  [IF QA3 = No] Which questions did you 
have trouble understanding and why?  [text box]   QA3_comment   
PAGE BREAK       
Quality 
Assurance  Would you do this study again?  0=No  
1=Yes   QA4   
44 
 Construct  
(Source)  Question Text  Response Option  Pretest Var Name  Post 1 Var Name  Post 2 Var Name  
Quality 
Assurance  Would you recommend this study to a 
friend?  0=No  
1=Yes   QA5   
Quality 
Assurance  Did anything annoy you, if so, what?  [text box]   QA6   
Quality 
Assurance  Is there anything that you would like to 
share about your experience in the study?  [text box]   QA7   
Quality 
Assurance  Did you have any difficulty remembering 
how many cigarettes you smoked? If yes, 
please explain.  [text box]   QA8   
Quality 
Assurance  Would you have preferred to receive the 
surveys for this study via text message?  0=No  
1=Yes   QA9   
PAGE BREAK       
Instructions 
for Enrolling 
in Survey 
Signal  On the next page, you will be redirected to 
a new link (SurveySignal).  It is very 
important that you fill out the information 
on that page  (including name, email 
address, etc.). If you do not fill out that 
information, you will NOT be enrolled in 
the study. If you have any questions, email 
Project3@unc.edu . 
 
Once you fill in your information, 
SurveySig nal will send you an email to 
verify your email address. Please make sure 
that you verify your email, so that you will 
be enrolled in the study.  
 
Note:  If you are using a Mac, you will need 
to open the link in Chrome or Firefox.   SurveySignal_Inst    
End of 
Survey for 
anyone that 
is no longer a Unfortunately you are no longer eligible for 
our study. We will send you a check for $20 
to compensate you for your time 
completing this survey, but you will not b e 
able to complete the rest of the study.      
45 
 Construct  
(Source)  Question Text  Response Option  Pretest Var Name  Post 1 Var Name  Post 2 Var Name  
smoker 
(smoke_stat_
pre =0)   
Thank you for taking the time to complete 
this survey!  
46 
 Morning Questionnaire  (to be answered between 7am – 11am every morning)  
Construct  (Source)  Question Text  Response Option  Var Name  
Study ID  [Auto -recorded]  numerical   
Behavior 
Instructions  Please think about yesterday   Behav_Inst  
 What time did you wake up yesterday?  Time  Time#1_Wake_Hour  
Time#1_Sleep_Hour  
Time#2_Wake_Min  
Time#2_Sleep_Min  
Time#3_Wake_AMPM  
Time#3_Sleep_AMPM    What time did you go to sleep last night?  Time  
Behavior4 How many times yesterday did you dispose of your cigarette 
butts by dropping them on the ground?  Dropdown list 0 -100, 101=refused  Lit1 
How many times yesterday did you dispose of your cigarette 
butts by throwing them or dropping them out of the car 
windo w? Lit2 
How many times yesterday did you stop yourself from having a 
cigarette because you wanted to smoke less?  Forgo  
How many times yesterday did you butt out a cigarette before 
you finished because you wanted to smoke less?  Butt  
PAGE BREAK     
Cigarettes Smoked7 Yesterday, from the time you woke up until noon, how many 
cigarettes did you smoke?  Dropdown list 0 -100, 101=refused  Cigs_Morn  
Yesterday, from noon until you went to sleep, how many 
cigarettes did you smoke?  Cigs_Afternoon  
PAGE BREAK     
Thinking 
Instructions4 Overall yesterday, how much did you…   Think  
Thinking About 
Chemicals4 Think about the chemicals in the smoke from your cigarettes?  5=All  of the time  
4=Often  
3=Sometimes  
2=Rarely  
1=Never  Think_Chem  
Thinking About 
Risks  Think about the harm your smoking might be doing to you?  Think_Risk  
Thinking About 
Littering  Think about discarding cigarette butts properly?  Think_Lit  
Thinking about 
quitting  Think about quitting smoking?  Think_Quit  
47 
 Construct  (Source)  Question Text  Response Option  Var Name  
PAGE BREAK     
Instruction  Please view the message on the next screen. After 10 seconds , 
you will be able to click the ‘>>’ to move forward to the next 
page . 
 
[Messages should appear at the top of the screen for all 
subsequent questions]   Morn_Inst1  
Page Break     
Message  Condition 1 or 2(Arsenic, Formaldehyde, Uranium, Ammonia, 
Lead) Or Control Messages  [This should appear on the screen 
for 10 seconds before participants are able to move on to 
questions on the next page]   Message  
Page Break     
Affect Instruction  How much did the message make you feel…   Affect_Inst  
Affect25–27 Anxious?  5=Extremely   
4=Very  
3=Somewhat  
2=A little  
1=Not  at all 
 Affect_1  
Sad?  Affect_2  
Scared?  Affect _3 
Guilty?  Affect _4 
Disgusted?  Affect _5 
Page Break     
Credibility28 Please indicate how much you think the message is…   Cred_Inst  
Accurate  7 = Very accurate  
1 = Not very accurate  
 Cred_1  
Authentic  7 = Very authentic  
1 = Not very authentic  
 Cred_2  
Believable  7 = Very believable  
1 = Not very believable  
 Cred_3  
Page Break     
48 
 Construct  (Source)  Question Text  Response Option  Var Name  
Instruction  Please select the bubble to show how much you agree or 
disagree with the statements below:   PE_Inst  
Perceived 
Effectiveness29 The message makes me concerned about the health effects of 
smoking.  5=Strongly agree  
4=Somewhat agree  
3=Neither agree nor disagree  
2=Somewhat disagree  
1=Strongly disagree  
 
 
 PE_1  
The message makes smoking seem unpleasant to me.  PE_2  
The message discourages me from wanting to smoke.  PE_3  
PAGE BREAK     
 How many cigarettes do you think you will smoke today?  Dropdown list 0 -100, 101=refused  Cigs_Predict  
PAGE BREAK     
End of Survey  You’re on day X of the 15 days of morning surveys. You’ve 
completed X morning survey(s) so far. We appreciate your 
response(s). Thank you!    
 
  
49 
 References for Measures  
 
1.  The GenIUSS Group. Best Practices for Asking Questions to Idenfity Transgender and Other Gender Minority Respondents on Population -Based Surveys .; 
2014. https://williamsinstitute.law.ucla.edu/wp -content/uploads/geniuss -report -sep-2014.pdf. Accessed June 22, 2018.  
2.  Sexual Minority Assessment  Research Team (SMART). Best Practices for Asking Questions about Sexual Orientation on Surveys .; 2009. 
https://williamsinstitute.law.ucla.edu/wp -content/uploads/SMART -FINAL -Nov-2009.pdf. Accessed June 22, 2018.  
3.  Boynton MH, Agans RP, Bowling JM, et al.  Understanding how perceptions of tobacco constituents and the FDA relate to effective and credible tobacco 
risk messaging: A national phone survey of U.S. adults, 2014 –2015. BMC Public Health . 2016;16(1):516. doi:10.1186/s12889 -016-3151 -5 
4.  Brewer NT, J eong M, Mendel JR, et al. Cigarette pack messages about toxic chemicals: a randomised clinical trial. Tob Control . April 
2018:tobaccocontrol -2017 -054112. doi:10.1136/tobaccocontrol -2017 -054112  
5.  Department of Health and Human Services. 2017 Annual Update  of the HHS Poverty Guidelines . Vol 82.; 2017. https://www.gpo.gov/fdsys/pkg/FR -2017 -
01-31/pdf/2017 -02076.pdf. Accessed June 22, 2018.  
6.  Schmidt AM, Jarman KL, Ranney LM, et al. Public Knowledge and Credibility Perceptions of the FDA as a Tobacco Regulat or. Nicotine Tob Res . September 
2017. doi:10.1093/ntr/ntx215  
7.  Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagers tröm Tolerance 
Questionnaire. Br J Addict . 1991;86(9):1119 -1127. h ttp://www.ncbi.nlm.nih.gov/pubmed/1932883. Accessed February 25, 2018.  
8.  Fagan P, Augustson E, Backinger CL, et al. Quit attempts and intention to quit cigarette smoking among young adults in the Un ited States. Am J Public 
Health . 2007;97(8):1412 -1420. d oi:10.2105/AJPH.2006.103697  
9.  Centers for Disease Control and Prevention. 2016 Behavioral Risk Factor Surveillance System Questionnaire .; 2016.  
10.  Klein WMP, Zajac LE, Monin MM. Worry as a Moderator of the Association Between Risk Perceptions and Quitt ing Intentions in Young Adult and Adult 
Smokers. Ann Behav Med . 2009;38(3):256 -261. doi:10.1007/s12160 -009-9143 -2 
11.  Thrasher JF, Swayampakala K, Borland R, et al. Influences of Self -Efficacy, Response Efficacy, and Reactance on Responses to Cigarette He alth Warnings: 
A Longitudinal Study of Adult Smokers in Australia and Canada. Health Commun . 2016;31(12):1517 -1526. doi:10.1080/10410236.2015.1089456  
12.  Thrasher JF, Swayampakala K, Cummings KM, et al. Cigarette package inserts can promote efficacy belie fs and sustained smoking cessation attempts: A 
longitudinal assessment of an innovative policy in Canada. Prev Med (Baltim) . 2016;88:59 -65. doi:10.1016/j.ypmed.2016.03.006  
13.  IARC HANDBOOKS OF CANCER PREVENTION. Int Agency Res Cancer World Heal Organ . 12. http://www.iarc.fr/en/publications/pdfs -
online/prev/handbook12/Tobacco_vol12_cover.pdf. Accessed June 21, 2018.  
14.  Rice EL, Fredrickson BL. Do positive spontaneous thoughts function as incentive salience? Emotion . 2017;17(5):840 -855. doi:10.1037/emo000 0284  
15.  Orbell S, Hagger M. Temporal framing and the decision to take part in type 2 diabetes screening: Effects of individual differ ences in consideration of 
future consequences on persuasion. Heal Psychol . 2006;25(4):537 -548. doi:10.1037/0278 -6133.25.4 .537  
16.  Regan AK, Promoff G, Dube SR, Arrazola R. Electronic nicotine delivery systems: adult use and awareness of the “e -cigarette” in the USA. Tob Control . 
2013;22(1):19 -23. doi:10.1136/tobaccocontrol -2011 -050044  
50 
 17.  Lazard AJ, Byron MJ, Vu H, Peters E, Schmidt A, Brewer NT. Website Designs for Communicating About Chemicals in Cigarette Smoke. Health Commun . 
2019;34(3):333 -342. doi:10.1080/10410236.2017.1407276  
18.  Rohde JA, Noar SM, Horvitz C, Lazard AJ, Ross JC, Sutfin EL. The role of knowledge and risk beliefs in adolescent E -cigarette use: A pilot study. Int J 
Environ Res Public Health . 2018;15(4). doi:10.3390/ijerph15040830  
19.  Ferrer RA, Klein WMP, Persoskie A, Avishai -Yitshak A, Sheeran P. The tripartite model of risk perception (TRIRISK): dist inguishing deliberative, affective, 
and experiential components of perceived risk. Ann Behav Med . 2016;50(5):653 -663. doi:10.1007/s12160 -016-9790 -z 
20.  Kessler RC, Barker PR, Colpe LJ, et al. Screening for serious mental illness in the general population.  Arch Gen Psychiatry . 2003;60(2):184 -189. 
doi:10.1001/archpsyc.60.2.184  
21.  Osman A, Kowitt SD, Sheeran P, Jarman KL, Ranney LM, Goldstein AO. Information to Improve Public Perceptions of the Food and Drug Administration 
(FDA’s) Tobacco Regulatory Role. Int J Environ Res Public Health . 2018;15(4). doi:10.3390/ijerph15040753  
22.  Hall MG, Sheeran P, Noar SM, et al. Negative affect, message reactance and perceived risk: how do pictorial cigarette pack wa rnings change quit 
intentions? Tob Control . December 2017:tobaccocontrol -2017 -053972. doi:10.1136/tobaccocontrol -2017 -053972  
23.  Morgan JC, Southwell BG, Noar SM, Ribisl KM, Golden SD, Brewer NT. Frequency and Content of Conversations About Pictorial Warn ings on Cigarette 
Packs. Nicotine Tob Res . 2018;20(7):882 -887. https://pubmed.ncbi.nlm.nih.gov/29059415/. Accessed July 13, 2020.  
24.  Noar SM, Rohde JA, Horvitz C, Lazard AJ, Cornacchione Ross J, Sutfin EL. Adolescents’ receptivity to E -cigarette harms messages delivered using text 
messaging. Addict Behav . June 2018. doi:10.1016/j.addbeh.2018.05.025  
25.  Nonnemaker J, Farrelly M, Ka myab K, Busey A, Mann N. Experimental Study of Graphic Cigarette Warning Labels: Final Results Report .; 2010. 
http://www.tobaccolabels.ca/wp/wp -content/uploads/2013/12/USA -2010 -Experimental -Study -of-Graphic -Cigarette -Warning -Labels -Final -Results -
Report -FDA.pdf. Accessed July 11, 2018.  
26.  Keller PA, Block LG. Increasing the persuasiveness of fear appeals: The effect of arousal and elaboration. J Consum Res . 1996;22(4):448 -459. 
doi:10.1086/209461  
27.  Watson D, Clark L, Tellegen A. Development and validatio n of brief measures of positive and negative affect: the PANAS scales - PubMed. J Pers Soc 
Psychol . 1988;54(6):1063 -1070. https://pubmed.ncbi.nlm.nih.gov/3397865/. Accessed August 7, 2020.  
28.  Appelman A, Sundar SS. Measuring Message Credibility. Journal Mass Commun Q . 2016;93(1):59 -79. doi:10.1177/1077699015606057  
29.  Baig SA, Noar SM, Gottfredson NC, Boynton MH, Ribisl KM, Brewer NT. UNC Perceived Message Effectiveness: Validation of a Brie f Scale. Manuscr 
Submitt Publ . 2018.  
 
 
  
Appendix B: Trial Consent Form  
University of North Carolina at Chapel Hill  
Consent to Participate in a Research Study  
Adult Participants  
 
Consent Form Version Date: V6, December 18, 2017  
IRB Study #  17-0610  
Title of Study : Enhancing Source Credibility in Tobacco Regulatory Communications - Aim 3 RCT  
Principal Investigator : Adam Goldstein  
Principal Investigator Department : Family Medicine  
Principal Investigator Phone number : (919) 966 -4090  
Principal Investigator Email Address : aog@med.unc.edu  
Co-Investigators: Leah Ranney, Seth Noar, Paschal Sheeran  
Funding Source and/or Sponsor:  National Institutes of Health (NIH)  
Study Coordinator Contact: Kristen Jarman  
Study Contact Telephone Number : (919) 966 -3016  
Study Contact Email : project3@unc.edu  
 
_________________________________________________________________  
 
What are some general things you should know about research studies?  
You are being asked to take part in a research study.   To join the study is voluntary.  
You may choose n ot to participate, or you may withdraw your consent to be in the study, for any reason, 
without penalty.  
 
Research studies are designed to obtain new knowledge. This new information may help people in the 
future.    You may not receive any direct benefit fr om being in the research study. There also may be risks to 
being in research studies.  
 
Details about this study are discussed below.   It is important that you understand this information so that you 
can make an informed choice about being in this research  study.   
 
You will be given a copy of this consent form.   You should ask the researchers named above, or staff members 
who may assist them, any questions you have about this study at any time.  
 
What is the purpose of this study?  
The purpose of this researc h study is to learn how people respond to messages about cigarette use. We will be 
asking participants to complete several surveys over 33 days, to get unique data about how people respond to 
messages about cigarettes.  
 
Who should take part in the study?  
Only participants that have been asked to enroll in the study are eligible. If you did not receive an email 
invitation to take part in the study, and you enroll anyway, you will be removed from the study. 
Additionally, each person can only enroll in the st udy once.  
 
How many people will take part in this study?  
There will be approximately 1000 people in this research study.  
 
How long will your part in this study last?  
52 
 Your part in the study will be to answer surveys delivered to your email over 33 days.  
 
What will happen if you take part in the study?  
You will receive emails during the study period to invite you to complete surveys. The chart below describes 
which days you will receive surveys and how long they will be.
 
What are the possible benefits from being in this study?  
 By taking part in this study, participants may increase their knowledge of the health risks associated with 
tobacco use. All participants may experience personal satisfaction of knowing they have contributed to a 
researc h project aimed at understanding tobacco risk communications.  
 
What are the possible risks or discomforts involved from being in this study?  
Sometimes things happen to people in research studies that may make them feel bad. These are called “risks.” 
Taking  part in this research study may involve telling us about your opinions or behaviors that you consider to 
be private or that cause you embarrassment. We will take steps to keep your information safe and private.  
There may be uncommon or previously unknown risks. You should report any problems to the researcher.  
 
What if we learn about new findings or information during the study?  
You will be given any new information gained during the course of the study that might affect your willingness 
to continue your participation.   
 
How will information about you be protected?  
Participants will not be identified in any report or publication about this study. Although every effort will be 
made to keep research records private, there may be times when federal or state l aw requires the disclosure of 
such records, including personal information. This is very unlikely, but if disclosure is ever required, UNC -
Chapel Hill will take steps allowable by law to protect the privacy of personal information. In some cases, your 
information in this research study could be reviewed by representatives of the University, research sponsors, or 
government agencies (for example, the FDA) for purposes such as quality control or safety.  
What if you want to stop before your part in the study i s complete?  
You can withdraw from this study at any time, without penalty.   The investigators also have the right to stop 
your participation at any time. This could be because you have had an unexpected reaction, or have failed to 
follow instructions, or b ecause the entire study has been stopped.  
Will you receive anything for being in this study?  
You will be receiving a check for up to $150 for taking part in this study. The amount of the check is based on 
the number of study surveys that you complete.  
At the beginning (day 1), middle (day 17) and end (day 33) of this study there are 3 surveys that will take about 
20 minutes to complete. You will be paid $20 for each of these surveys that you complete, for up to $60.  
For 15 days (from day 2 through day 16) d uring this study, you will receive a survey in the morning that will 
last about 5 minutes each to complete, you must complete this survey between 7am and 11am. You will be paid 
$4 for each morning survey, but you can only take one morning survey each day. You can also earn bonuses for 
completing these survey.  Day 1 -
20 minute surveyDay 2 -Day 16
•Morning -5 min 
surveyDay 17 -
20 minute surveyDay 33 -
20 minute survey
53 
 When data collection for the full study is complete, we will have a drawing for three additional Amazon gift 
cards, with a $200 value. Entries into the drawing will be based on completion of the mornin g surveys.  
Bonus system for Survey Completion:  
• Bronze: Total of $10 bonus for at least 9 morning surveys. 1 entry into Amazon gift card drawing.  
• Silver: Total of $20 bonus for at least 12 morning surveys. 2 entries into Amazon gift card drawing.  
• Gold: Total of $30 for completing all 15 morning surveys. 3 entries into Amazon gift card drawing.  
For Example: If Amy completes 2 of the 3 surveys that take 20 minutes, and 13 morning surveys, then she 
would get:  
• 2 x $20 for 20 minute surveys = $40  
• 13 x $4 for morning surveys = $52  
• Silver level for survey completion = $20  
• Amy’s Check Amount = $112  
Within 4 -6 weeks of completing the study, you will be mailed the check for surveys that you have 
completed.  
If you win the drawing for the Amazon gift card, we will em ail you the gift card within 7 days of the 
drawing.  
Will it cost you anything to be in this study?  
If you enroll in this study, you will have costs related to completing the surveys on the internet. If you use your 
phone to complete the surveys, this may c ost you a small amount of data from your mobile phone plan which 
will not be covered by the study.  
Who is sponsoring this study?  
This research is funded by the National Cancer Institute. This means that the research team is being paid by the 
sponsor for do ing the study.  The researchers do not, however, have a direct financial interest with the sponsor 
or in the final results of the study.  
 
What if you have questions about this study?  
You have the right to ask, and have answered, any questions you may have about this research. If you have 
questions about the study (including payments), complaints, concerns, or if a research -related injury occurs, you 
should contact the researchers listed on the first page of this form.  
 
What if you have questions about your rights as a research participant?  
All research on human volunteers is reviewed by a committee that works to protect your rights and welfare.   If 
you have questions or concerns about your rights as a research subject, or if you would like to obtain 
informat ion or offer input, you may contact the Institutional Review Board at 919 -966-3113 or by email to 
IRB_subjects@unc.edu.  
Participant’s Agreement : 
 
I have read the information provided above.   I have asked all the questions I have at this time.   I voluntaril y 
agree to participate in this research study.  
 
 [Check Box]  